Pivya™ (pivmecillinam) – New drug approval
April 24, 2024 - The FDA announced the approval of Utility Therapeutics’ Pivya (pivmecillinam), for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (UTI) caused by susceptible isolates of Escherichia coli (E. coli), Proteus mirabilis, and Staphylococcus saprophyticus.
Top